Xeomin: How It Differs from Botox and Which Lines It Treats

You would like your frown lines to look softer without losing familiar facial expression. After hearing the name Xeomin, you may wonder how it differs from “Botox” and whether the result is predictable. Xeomin is a prescription medicine containing incobotulinumtoxinA (botulinum toxin type A), made by Merz. It is a neuromodulator injected into selected muscles, where it temporarily reduces nerve-to-muscle signalling. It is not a filler, a skin booster or a product that fills a groove or restores lost facial volume.

For certain dynamic upper-face lines in adults, its temporary cosmetic effect has been demonstrated. How natural the face looks depends on individual anatomy and injection planning, not a promise of a particularly “pure” preparation. Contraindications, the possibility of a drooping brow or eyelid, the timing of the result and the clinician's ability to preserve your individuality all matter.

What is Xeomin, and what does “free of complexing proteins” mean?

Its active ingredient in the prescribing information is incobotulinumtoxinA. During manufacture the active neurotoxin is separated from associated bacterial proteins, often called complexing or accessory proteins. This explains the description “without accessory proteins.” It is a formulation characteristic, not evidence of zero allergy risk, a completely absent immune response or an invariably longer effect than every competing botulinum toxin. The vial also contains human albumin and sucrose. Tell the clinician about known reactions to any component.

In everyday conversation “Botox” is often used for the whole drug class, although Botox is a trade name for onabotulinumtoxinA, a different product. Dysport and other neuromodulators have their own formulations, dosing systems and instructions. Xeomin's US label specifically warns that activity units of different botulinum toxin products cannot simply be converted. Even when a comparative study uses the same nominal number of units, that does not create a conversion chart suitable for every patient or anatomical site.

After injection the toxin temporarily inhibits the release of acetylcholine, the signal that makes muscles contract. As a targeted expression muscle contracts less forcefully, overlying skin creases less. The product does not remove the muscle or permanently stop a person's expressions. Function gradually returns, so the effect is reversible, although unpleasant adverse effects may also last weeks and should not be dismissed.

Which wrinkles have an established indication?

The June 2026 revision of the US Xeomin prescribing information (the DailyMed page was updated on 10 July 2026) lists the temporary improvement of moderate-to-severe upper facial lines in adults: glabellar frown lines caused by corrugator and/or procerus activity; horizontal forehead lines involving the frontalis; and lateral canthal or crow's-feet lines involving orbicularis oculi. Separate medical uses—certain spasticity disorders, blepharospasm, cervical dystonia and excessive salivation—do not make the drug suitable for every cosmetic concern. Indications and labelling vary between countries; neither Armenian registration nor stock in any clinic follows from the US label.

Dynamic lines, which appear or deepen during movement, generally respond most clearly. A deep crease visible even with the face fully relaxed may soften but need not disappear; sun damage, skin thickness and established dermal changes also contribute. Under-eye bags, tear-trough hollows, loss of temple volume and descended tissues are different problems. If upper lids are already hooded, carefully assess how the forehead muscle helps hold the brows up: weakening it excessively can make the eyes look heavier.

First identify what creates the line

What do the trials establish, and what do they not promise?

Two phase III randomised trials, ULTRA I and ULTRA II, compared incobotulinumtoxinA with placebo for simultaneous treatment of glabellar, forehead and outer-eye lines. A total of 362 and 368 people respectively received treatment; at day 30 the drug outperformed placebo on key study measures. This is stronger evidence than clinic photographs. Still, trial subjects met entry criteria, and an improvement on wrinkle scales does not guarantee that every woman will find the appearance ideal.

In a direct randomised comparison involving 250 women with glabellar lines, 20 units of incobotulinumtoxinA and 20 units of onabotulinumtoxinA produced similar results at one month and during follow-up up to four months. This supports comparable efficacy in that particular setting, not universal interchangeability of drugs, doses or sites. The claim that “Xeomin never causes resistance” is also too strong: repeat response can depend on dose, intervals, muscle activity and other factors. Possible immunologic nonresponse requires assessment, not self-diagnosis after one disappointing visit.

The US label describes median onset in 2–7 days and typical duration up to 12–16 weeks, with individual variation. These are planning estimates, not a guarantee of perfectly smooth skin for exactly four months. Some research reports longer improvements, but outcomes of specific protocols and samples cannot be promised to everyone. Under US labelling retreatment should be no more frequent than every three months; requests for an immediate “extra top-up tomorrow” need medical assessment, not automatic agreement.

How can expression look natural rather than frozen?

Naturalness is not an inherent property of the vial. It is a balance between reducing creases and retaining the movement you value. Before injecting, have the clinician look at your relaxed face, frown, eyebrow raise, speech and smile. Muscles can differ in strength between sides, and some people unconsciously raise their brows to compensate for loose eyelid skin. A standard map of identical points for everyone overlooks individual expression anatomy.

Explain what would feel overdone: inability to raise a surprised brow, a noticeably altered smile, lower outer brow ends or loss of every animated line. Agree on an achievable compromise rather than requesting “the most units for the money.” A lighter effect can preserve more movement and some wrinkles without being a failure. If you want to look as though nothing has been done, ask precisely which movements are likely to remain and which will weaken.

The relationship between frown muscles and forehead matters: relaxing one group can redistribute muscle pull and change brow position. Do not choose injection points from someone's social-media diagram. This is a prescription drug; self-reconstitution, storage and injection are unsafe and inappropriate.

What happens on injection day and over the following week?

The consultation covers diagnoses, allergies, previous botulinum injections, current medications, pregnancy and breastfeeding; facial motion may be photographed with consent. A qualified clinician uses a fine needle to inject chosen muscles. Expect brief pinpricks, stinging, pinpoint bleeding or bruising. Even good technique cannot guarantee a mark-free face. Dose, position and number of injections must be individualised within applicable labelling and clinical circumstances, not selected by a “price per wrinkle” offer.

Immediately afterwards the face often looks unchanged because the medicine has not taken full effect. Small bumps, soreness or redness can occur in the first hours and bruising may be visible over subsequent days. Do not schedule it the day before a wedding, important photos or a presentation: onset takes time and unexpected asymmetry needs a buffer. Evaluate the developed movement with the clinician, not the mirror 20 minutes after injection.

Obtain written aftercare advice; do not massage injection sites on your own, especially without understanding any effect on spread. Ask your treating clinician about exercise, makeup, head position and skincare procedures. There is no universal evidence-based ban on every activity for two weeks, but bruising, pain or other symptoms change individual advice. Agree on the follow-up plan and reasons to seek help immediately.

Who should not receive Xeomin, or needs particular caution?

Under the US label, contraindications are known hypersensitivity to any botulinum toxin product or Xeomin ingredient, and infection at the proposed injection site. Extra caution is required with neuromuscular transmission disorders such as myasthenia gravis or Lambert–Eaton syndrome, muscle weakness, breathing or swallowing problems, pronounced asymmetry and pre-existing brow or eyelid ptosis. In such cases muscle weakness can have consequences far beyond cosmetic discomfort.

Certain aminoglycoside antibiotics, muscle relaxants and other drugs affecting neuromuscular signalling can potentiate the toxin; another toxin treatment in recent months also matters. Do not stop a prescribed medicine yourself: tell the clinician the names, doses and dates. During pregnancy, elective aesthetic injections are best postponed because adequate human safety data are lacking and reproductive effects occurred under some animal-study conditions. Whether Xeomin passes into human milk or affects an infant is insufficiently understood. Medical indications require a separate risk-benefit decision, whereas elective aesthetic use can reasonably wait.

In cosmetic studies common reactions included bruising or haematoma and headache, and sometimes brow droop; local muscle weakness, asymmetry, eyelid ptosis or a changed smile are possible. More serious effects can occur rarely: the prescribing information has a prominent boxed warning about toxin effects spreading beyond the injection site. New double vision, marked weakness, speech, swallowing or breathing difficulty occurring hours to weeks after an injection needs urgent medical assessment; problems swallowing or breathing require emergency help. Do not assume a dangerous symptom will disappear when the cosmetic effect fades.

When the result causes concern

Xeomin versus other neuromodulators and fillers

Xeomin and Botox are both botulinum toxin type A products but are distinct brands with different instructions. Country-specific indications, preparation, activity units and storage conditions may differ. Do not choose based only on “most purified” or “strongest.” The practitioner must know the exact product and explain the change to your expressions. Equivalence studies for particular situations do not make arbitrary vials or doses interchangeable.

A hyaluronic-acid filler adds volume or changes contour; it does not relax a muscle by the same mechanism, and its vascular risks and uses are different. Skincare and sun protection help skin quality but do not block a strong expression muscle. Choosing no treatment is reasonable: expression lines do not require medical correction. If the real issue is significant skin descent, an anatomical consultation is more useful than trying higher toxin doses.

What should you verify before paying and consenting?

Ask for the exact commercial name, active ingredient, country-specific authorisation, vial provenance, expiry date, storage conditions and qualifications of the injector. Why these muscles? How will the brows and eyelids be protected? How much movement should remain, when should results appear and what if asymmetry develops? Ask about serious warnings, not only before-and-after images.

The quote should distinguish the consultation, product and any clinically justified follow-up correction; no local price can be asserted without verifiable offers. A product appearing online does not prove it is in stock in Yerevan or a given office. Decline if the packaging and drug details are concealed, you are rushed into signing consent, risk-free results are promised or your wish to retain expression is ignored.

The central point: Xeomin is a studied prescription neuromodulator with evidence for defined dynamic upper-face lines, but it is neither an all-purpose eraser nor inherently superior to every alternative toxin. Useful decisions begin with observing your individual facial movement, verifying the product and understanding the real risks.